• Users Online: 3687
  • Print this page
  • Email this page
Year : 2022  |  Volume : 6  |  Issue : 1  |  Page : 19-22

Mineral bone disorders in hemodialysis patients in the West of Libya

1 Department of Nephrology, Sabratha Teaching Hospital, Sabratha, Libya
2 Department of Hemodialysis, AZ Zawiyah Kidney Hospital, Az-zawiyah, Libya
3 Department of Dialysis, Surman General Hospital, Surman, Libya
4 Department of Hemodialysis, Agelat Hospital, Al Agelat, Libya
5 Department of Hemodialysis, Algmail Hospital, Al Gmail, Libya
6 Department of Hemodialysis, Hemodialysis Unit, Zawara Hospital, Zawara, Libya

Correspondence Address:
Dr. Khairi Ayad
Department of Nephrology, Sabratha Teaching Hospital, Sabratha
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ljms.ljms_38_21

Rights and Permissions

Background and Objectives: Chronic kidney disease (CKD) is affecting 5%–10% of the world population. As kidney function declines, there is progressive deterioration in minerals homeostasis manifesting as disruption of serum and tissue concentrations of phosphorus, calcium (Ca), and parathyroid hormone (PTH). CKD-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism manifested by any or a combination of the following: abnormalities of Ca, phosphorus, PTH, Vitamin D metabolism, abnormalities of bone turnover, and vascular or soft-tissue calcification, associated with fractures, cardiovascular disease, and mortality in CKD patients. The study aims to identify the prevalence and pattern of CKD-MBD among hemodialysis patients in the west of Libya. Patients and Methods: A cross-sectional study was carried out on 186 regular hemodialysis patients from five hemodialysis centers in the west of Tripoli-Libya District. All patients were investigated for complete blood count, blood sugar, serum albumin, blood urea, serum creatinine, total Ca level, serum phosphate, serum alkaline phosphatase, and serum intact PTH (iPTH) level. Results: According to the Kidney Disease Outcomes Quality (KDOQ) iPTH level guideline, 88.10% of the studied patients had metabolic bone disorders, and 39.80% showed low bone turnover. About 48.40% were high bone turnover; only 11.80% of studied patients were within the target range according to the KDOQ Initiative guidelines. About 40.36% of studied patients had low calcium levels (below 8.5 mg%), and 35.48% had high phosphorus levels (more than 5.5 mg%). About 61.10% of high bone turnover patients complain of bone pain and 50.50% complain of muscle weakness. Among low bone turnover patients, 36.48% had no symptoms, and 28.38% were complaining of both muscle weakness and bone pain. Conclusions: The prevalence of MBDs among studied patients with abnormal PTH levels is 87.6%, distributed as 39.2% in abnormal low PTH (low bone turnover), and 48.4% in abnormal high PTH (high bone turnover).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded119    
    Comments [Add]    

Recommend this journal